KALA BIO, Inc.
KALA
Clasificación en acciones
#30843
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the... Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Precio por acción
$0.75
Última sincronización: 2026-07-31
Capitalización bursátil
$14.50M
Cambio (1 día)
2.78%
Cambio (1 año)
-98.42%
País
US
Comercio KALA BIO, Inc. (KALA)
Categoría
Healthcare
Ganancias de KALA BIO, Inc. (KALA)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di KALA BIO, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de KALA BIO, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
